← board
AMPH
Amphastar Pharmaceuticals, Inc.distress 1/10 · well-funded / low risk$19.18-1%today-38% from 52w high
amphastar.com1,976 employeesFounded 1996Rancho Cucamonga, CADrug Manufacturers - Specialty & Generic
Lead: Pharmacokinetics
Revenue
$171M
Liquidity
$294M
Runway
—
Shares 1y
-5%
Price & events
-26.6% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.6%
1D
-3.4%
1W
-1.8%
1M
-8.7%
3M
-26.0%
6M
-15.2%
1Y
-52.7%
2Y
-8.0%
5Y
-4.7%
All
Overview
- Market Cap
- $845.92M
- Enterprise Value
- $1.29B
- Volume
- 18.91K
- 52 Week Range
- $16.87 – $30.81
- Total Shares
- 44.09M
- Float Shares
- 32.83M
- Short %
- 18.25%
- % Held by Insiders
- 29.74%
- % Held by Institutions
- 77.27%
- RVOL
- 0.04x
- Beta
- 0.89
Pipeline stages · 1 programs
I004, NovoLog
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-06 | Phase 2/3 | I004, NovoLog | Pharmacokinetics, Pharmacodynamics, Insulin Aspart | 60 | recruiting |
Catalyst news & presentations · 3
- 2026-08-06Estimated 45%earningsEarningsEarnings releaseyahoo
- 2026-01-06partnershipCorticotropin, Lidocaine, Semaglutide · Exclusive license for corticotropin in US/Canada; distribution and manufacturing amendments expand territories for corticotropin, lidocaine, and semaglutide.SEC 8-K
- 2025-08-08partnershipthree proprietary peptides · Exclusive license agreement with Nanjing Anji for three peptides targeting oncology and wet AMD.SEC 8-K
Approved drugs (5)
- REXTOVYNALOXONE HYDROCHLORIDE2023 · Prescription
- BAQSIMIGLUCAGON2019 · Prescription
- AMPHADASEHYALURONIDASE2004 · Prescription
- DUOCAINEBUPIVACAINE HYDROCHLORIDE2003 · Discontinued
- CORTROSYNCOSYNTROPIN1970 · Prescription
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
hold · target $22 (+15% upside) · 6 analysts
- 2026-06-29B of A SecuritiesNeutral → Underperform
- 2026-06-03BarclaysEqual-Weight
- 2026-05-14Wells FargoOverweight → Equal-Weight
- 2026-05-11Piper SandlerNeutral
- 2026-05-08NeedhamBuy → Hold
- 2026-04-21JefferiesBuy → Hold
Competitors — Pharmacokinetics
- ALZNAlzamend Neuro, Inc.$5M · D9
Recent news
- 2026-07-22VENU Selects Legends Global to Lead Venue Management at Regent Bank Amphitheater in Oklahoma - Business Wire
- 2026-07-22Quantedge Capital Pte Ltd Sells 78,200 Shares of Amphastar Pharmaceuticals, Inc. $AMPH - MarketBeat
- 2026-07-18Amphastar Pharmaceuticals (NASDAQ:AMPH) Screens as a High-Quality Stock with Deep Value Appeal - ChartMill
- 2026-07-17Sammy Hagar Brings His Hit Best of All Worlds Tour to Colorado Springs - Business Wire
- 2026-07-17Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Given Average Recommendation of "Reduce" by Brokerages - MarketBeat
- 2026-07-17(AMPH) Volatility Zones as Tactical Triggers - Stock Traders Daily
- 2026-07-16Has Amphastar Pharmaceuticals Bottomed Out After Its Steep Decline - Kavout | AI
- 2026-07-16Amphastar Pharmaceuticals (NASDAQ:AMPH) Share Price Crosses Below 50 Day Moving Average - Should You Sell? - MarketBeat
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.